Mills Pharmaceuticals' Acquisition

Mills Pharmaceuticals was acquired by Galena Biopharma on January 13, 2014.

Mills Pharmaceuticals owns the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide for the treatment of Essential Thrombocythemia (ET). GALE-401 (Ana…

Articles about Mills Pharmaceuticals' Acquisition: